Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

SIFI and Bausch Health Russia Announce Strategic Commercial Partnership

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

DOJ Launches West Coast Strike Force...

The United States Department of Justice has launched a...

AI Emergency Triage Study Shows Superior...

A Harvard-led study has found that advanced artificial intelligence...

Johnson & Johnson to Acquire Atraverse...

Johnson & Johnson has entered into a definitive agreement...

SIFI, a leading international ophthalmic company, announces it has entered into a strategic multi-year agreement with Bausch Health Russia to market its innovative products treating ophthalmic disorders in Russia.

Initial sales are expected in 2021, marketing 5 SIFI products, segments of a comprehensive and established ophthalmic portfolio. These include:

  • COLBIOCIN™, NETTAVISC™ and NETTACIN™, antibiotic solutions indicated for the treatment of external eye infections and available in multiple dosage forms;
  • OCTILIA™, an eye-drop solution indicated for the treatment of irritations, reddening, ocular congestion and itching due to allergic, chemical or physical causes;
  • MIRTILENE FORTE CAPSULES, a retinotrophic vasoprotective food supplement, helpful in cases of capillary fragility or vascular alterations due to diabetic retinopathy.

Bausch Health Russia will have the option to commercialize future SIFI products currently under development.

“SIFI is committed to continuous development and expansion and is pleased to announce this strategic partnership with Bausch Health Russia,” said Gilberto Dalesio, SIFI’s CCO. “By joining forces SIFI will strengthen its global footprint and establish its presence in Russia, one of the fastest growing pharmaceutical markets in the world, and will enable Russian eye care doctors to address a wide variety of ophthalmic disorders, delivering significant benefits to Russian patients.”

“Bausch Health is pleased to partner with SIFI, because together we can ensure Russian eye health doctors and their patients have greater access to these important ophthalmic medications,” said Cees Heiman, Vice President Europe/Russia Pharmaceuticals, Bausch Health.

About SIFI

SIFI is a leading ophthalmic company, headquartered in Italy, focusing on eye care since 1935. SIFI develops, manufactures and markets innovative therapeutic solutions for patients with ophthalmic diseases. SIFI is committed to improve patients’ quality of life through its R&D efforts, exporting products to more than 20 countries worldwide with commercial operations in Italy, Spain, France, Romania, Mexico and Turkey.

MEDICAL FAIR ASIA 2026
MEDICAL FAIR CHINA

Latest stories

Related stories

AI Emergency Triage Study Shows Superior Clinical Accuracy

A Harvard-led study has found that advanced artificial intelligence...

Johnson & Johnson to Acquire Atraverse Medical Platform

Johnson & Johnson has entered into a definitive agreement...

US Speeds Insurance Coverage for Breakthrough Medical Device

A new federal initiative in the United States is...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »